PMGC Holdings (ELAB) Stock News

PMGC Holdings Inc. (NASDAQ:ELAB) has completed the acquisition of AGA Precision Systems LLC, a California-based CNC machining company. AGA generated $1.39 million in revenue in 2024 and has maintained consistent profitability.

This strategic acquisition represents PMGC's second bolt-on purchase under its roll-up strategy, bringing the company's estimated total annualized revenue to over $2.25 million. The deal strengthens PMGC's position in aerospace, defense, and industrial markets while supporting the broader trend of U.S. manufacturing reshoring initiatives.

Pacific Sun Packaging, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has announced its first-time participation in the 2025 ITAD Summit in Las Vegas. The company will showcase its custom-engineered protective packaging solutions for IT hardware at Booth A07 on July 29-30, 2025 at The Bellagio.

Founded in 2011, Pacific Sun specializes in protective packaging for sensitive IT components including CPUs, DIMMs, SSDs, HDDs, and fiber-optic modules. Their solutions cater to OEMs, data centers, and ITAD firms, focusing on ESD safety, dimensional precision, and supply chain durability. The company aims to strengthen existing relationships with data center operators and develop new partnerships in IT lifecycle management.

PMGC Holdings Inc. (NASDAQ:ELAB) has completed the acquisition of Pacific Sun Packaging Inc., a specialized custom IT packaging company based in San Clemente, California. The acquisition brings significant value as Pacific Sun serves over 300 commercial clients, including data centers, technology manufacturers, and IT service providers.

The strategic acquisition is expected to generate over $2,000,000 in combined revenue for fiscal years 2023 and 2024. This move enhances PMGC's exposure to U.S. semiconductor and AI infrastructure growth while marking the launch of its strategic acquisition program targeting U.S. businesses. The acquisition is notably cash flow positive.

PMGC Holdings Inc. (Nasdaq: ELAB) has announced signing a non-binding Letter of Intent (LOI) to acquire an unnamed U.S.-based CNC machining company. The target company specializes in manufacturing high-complexity components for the aerospace and defense sectors, generating $4.5 million in annual revenue. The acquisition target is notable for serving multiple Tier-1 aerospace clients and holds both AS9100 and ISO 9001 certifications.

PMGC Capital LLC, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has publicly urged Alaunos Therapeutics (NASDAQ: TCRT) to accept a financing term sheet facilitated through a major Wall Street bank. The term sheet, presented to Alaunos' board on May 25, 2025, is described as a non-toxic, well-structured financing opportunity that could provide substantial capital while potentially creating significant shareholder value. PMGC Capital, which holds a significant ownership position in Alaunos, emphasizes that the opportunity is time-sensitive and represents a strategic path forward. The company commends Alaunos for maintaining a clean capital structure during challenging market conditions and expresses its commitment to working with Alaunos' leadership to enhance long-term shareholder value.

Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has initiated Phase II of its AI Development Program with Yuva Biosciences. The collaboration focuses on leveraging YuvaBio's proprietary MitoNova™ AI platform to discover novel treatments for obesity, type 2 diabetes, and cardiometabolic conditions. In Phase II, YuvaBio will use MitoNova™ to virtually screen a large library of drug-like small molecules, predicting candidates that could promote mitochondrial health in obesity and cardiac diseases. The platform will analyze chemical and bioactivity properties to identify opportunities for biological validation, culminating in a list of synthetic compounds targeting muscle preservation and metabolic health.

PMGC Holdings Inc. (NASDAQ: ELAB) has signed a non-binding Letter of Intent to acquire an established U.S.-based electronics contract manufacturing company. The target company, which has been operational for over 40 years, specializes in high-precision electrical and mechanical assembly, including printed circuit board manufacturing for commercial and industrial customers across the United States. The target company is reported to be cash-flow positive. This marks PMGC's second pending acquisition since April, highlighting the company's active M&A strategy, with additional acquisitions expected throughout the year.

NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has completed Phase I strategic review of EL-22, their oral myostatin-engineered probiotic. The study, conducted with Yuva Biosciences using their MitoNova™ AI technology, focused on EL-22's potential to combat muscle loss associated with GLP-1 weight loss drugs and age-related sarcopenia.

EL-22 uses genetically engineered Lactobacillus casei to stimulate the gut immune system against myostatin, a muscle growth inhibitor. The preclinical studies in mdx mice showed promising effects on antibody production, serum CK, body weight, motor function, and muscle histology. The company plans to initiate a Phase 2 proof-of-concept trial targeting GLP-1 users and pursue IND filing in the United States.

PMGC Holdings Inc. (NASDAQ: ELAB) has filed its Q1 2025 Quarterly Report on Form 10-Q with the SEC. The company operates through multiple subsidiaries including NorthStrive Biosciences, focused on aesthetic medicines and developing EL-22 for muscle preservation in obesity treatments; PMGC Research, leveraging Canadian research grants; and PMGC Capital, a multi-strategy investment firm. Management reports the company is well-capitalized with a strong balance sheet. Notably, PMGC announced a non-binding LOI on April 16, 2025, to acquire a profitable U.S.-based IT custom packaging company, aligning with its strategy of pursuing B2B acquisitions to drive revenue growth and enhance shareholder value.